FDA-approved PARPi (olaparib, niraparib, rucaparib, and talazoparib) are the first synthetic lethal targeted drugs to enter clinical practice and are currently used to treat ovarian, breast, pancreatic, or prostate cancer characterized by BRCA1/2 mutations [9]. Here, BRCA1 is linked to Familial prostate cancer.